Welcome to our dedicated page for Gelteq SEC filings (Ticker: GELS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gelteq Limited (GELS) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Gelteq submits annual reports on Form 20-F and current reports on Form 6-K, which together outline its financial condition, operating results and key corporate developments related to its gel-based oral delivery platform.
In a recent Form 6-K, Gelteq furnished unaudited condensed consolidated financial statements for a six-month period, along with management’s discussion and analysis of financial condition and results of operations. The filing also included Inline XBRL instance and taxonomy documents that structure the company’s financial data for electronic analysis. These materials help investors understand revenue trends, research and development spending, and other financial metrics associated with Gelteq’s activities in pharmaceuticals, nutraceuticals, medicinal cannabis and sports performance applications.
On this page, users can review Form 20-F annual reports for a comprehensive view of risk factors, business description, significant accounting policies and governance information, as well as Form 6-K current reports that capture interim financial updates and material announcements furnished to the SEC. For companies like Gelteq, which operate in drug delivery and healthcare technology, these filings often complement press releases on preclinical results, commercial agreements and collaborations.
Stock Titan enhances these documents with AI-powered summaries that explain complex sections of Gelteq’s filings in plain language. Real-time updates from EDGAR ensure that new 6-Ks, 20-Fs and related exhibits appear promptly, while structured access to Inline XBRL data supports more detailed analysis. Users can also locate information related to executive and director share transactions when such details are reported on the relevant SEC forms.
Gelteq Limited received a notice from Nasdaq on March 18, 2026 that its ordinary shares failed to meet the minimum bid price requirement of $1.00 for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The shares remain listed and continue trading under the symbol GELS.
The company has until September 14, 2026 to regain compliance. If its closing bid price is at least $1.00 for at least ten consecutive business days within this period, Nasdaq will confirm compliance. If Gelteq does not regain compliance by that date, it may qualify for an additional 180‑day grace period, potentially including actions such as a reverse stock split.
Gelteq Ltd filed an initial insider ownership report naming Paul Michael Wynne as a reporting person in his role as Chief Scientific Officer. This Form 3 establishes him as a company insider for disclosure purposes. The data shown includes no reported purchases, sales, acquisitions, or dispositions of Gelteq Ltd securities.
Gelteq Ltd director Szewach Simon H filed an initial ownership report showing indirect stakes held through family trusts. The trusts hold 338,197 Ordinary Shares and a Convertible Note issued in March 2026 with a principal amount of AUD$130,000, convertible into 65,000 Ordinary Shares at A$2.00 per share, expiring on July 1, 2026. He shares investment authority as a manager of the trustee entity and disclaims beneficial ownership beyond his pecuniary interest.
Gelteq Ltd executive Bradley Glenn Karp, Head of Sales and Marketing, filed an initial ownership report showing indirect control over 500,000 Ordinary Shares. The shares are held by trusts where he serves as manager and trustee entity, and he is a co-beneficiary. He disclaims beneficial ownership of these securities except for his pecuniary interest, and the filing does not report any new buy or sell transactions.
Gelteq Ltd Chief Executive Officer Nathan J. Givoni filed an initial Form 3 reporting indirect holdings in the company through family trusts. The filing lists 657,087 Ordinary Shares held indirectly by trust and a Convertible Note convertible into 15,000 Ordinary Shares at an exercise price of $2.0000 per share, expiring on July 1, 2026. A footnote explains he has shared investment authority as a manager of the trustee entity and is a co-beneficiary, and he disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Gelteq Limited files its Form 20-F annual report, detailing continued operating losses and substantial doubt about its ability to continue as a going concern. The company develops edible gel dosage forms and remains an early-stage business with limited sales and an unproven market. It reported total losses of approximately AUD$6,645,453 and AUD$3,546,195 for the fiscal years ended June 30, 2025 and 2024, and expects losses to continue as it funds research, product development, manufacturing and commercialization.
Management warns that significant additional financing will be required to pursue its plans, and failure to secure capital could force delays or cuts in development and marketing activities. Gelteq outsources manufacturing and relies on third-party licensees for marketing and distribution, creating supply, quality and partner-performance risks. Operations also face geopolitical and regulatory risks, including limited but growing exposure to China, heavy reliance on intangible assets, and concentrated ownership that may influence key shareholder decisions.